Approximately 50 million people in the US are affected by devastating diseases as a result of axonal degeneration and neuronal loss. It is possible to detect and slow axonal degeneration but it cannot be prevented, stopped or reversed. There are no effective neuroprotective treatments today. We intend to change that by directly targeting the underlying mechanisms of axonal degeneration.
Proneurotech is a biopharmaceutical company backed by The Column Group focused on discovering and developing neuroprotective drugs that prevent axon loss after acute injury or chronic degenerative disease.
Axon degeneration is a key pathological component in many acute and chronic neurologic and ocular conditions including traumatic brain injury, stroke, peripheral neuropathies, glaucoma and other optic neuropathies, Parkinson’s disease, motor neuron disease, and multiple sclerosis.
Recent insights from the founders of Proneurotech and others have highlighted the central role of nicotinamide adenine dinucleotide (NAD) in the preservation of axons across numerous disease models, revealing several new druggable targets that drive the synthesis or consumption of this cardinal metabolite.
We’re fighting to make a difference to change people’s lives with leading pioneering science and medicine to make breakthrough treatments for people with neurodegenerative diseases. Our team combines research in biochemistry, genetics, neurology, and synthetic chemistry to fuel mechanistic insights for discovering and developing novel, neuroprotective drugs that prevent axon degeneration for the treatment of neurologic and ocular diseases.